{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:36:37Z","timestamp":1791333397292,"version":"4.3.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001378"],"award-info":[{"award-number":["82001378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.yebeh.2021.107967","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T11:35:00Z","timestamp":1621078500000},"page":"107967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment"],"prefix":"10.1016","volume":"120","author":[{"given":"Junhong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-8919","authenticated-orcid":false,"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107967_b0005","first-page":"213","article-title":"Reversible valproic acid-induced parkinsonism and cognitive impairment in an elderly patient with bipolar disorder I","volume":"27","author":"Hassamal","year":"2016","journal-title":"Turk Psikiyatri Derg"},{"key":"10.1016\/j.yebeh.2021.107967_b0010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/appi.ajp.2019.18040363","article-title":"Fulminant onset of valproate-associated hyperammonemic encephalopathy","volume":"176","author":"Baumgartner","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.genhosppsych.2019.05.005","article-title":"Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions","volume":"59","author":"Duman","year":"2019","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.nrl.2019.05.010","article-title":"Non-convulsive status epilepticus secondary to valproate-induced hyperammonaemic encephalopathy","volume":"35","author":"Viloria Alebesque","year":"2020","journal-title":"Neurologia"},{"key":"10.1016\/j.yebeh.2021.107967_b0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bcpt.13049","article-title":"Risk factors for valproic acid-induced hyperammonaemia in chinese paediatric patients with epilepsy","volume":"123","author":"Zhu","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.yebeh.2021.107967_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00728","article-title":"Reversible valproate-induced subacute encephalopathy associated with a MT-ATP8 variant in the mitochondrial genome","volume":"9","author":"De Michele","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2021.107967_b0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management","volume":"34","author":"Chopra","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0040","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1442-200X.2010.03157.x","article-title":"Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia","volume":"52","author":"Yagi","year":"2010","journal-title":"Pediatr Int"},{"key":"10.1016\/j.yebeh.2021.107967_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2012.03532.x","article-title":"Topiramate increases the risk of valproic acid-induced encephalopathy","volume":"54","author":"Noh","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107967_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.psym.2017.02.003","article-title":"Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders","volume":"58","author":"Lewis","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.yebeh.2021.107967_b0055","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.wneu.2020.09.027","article-title":"Incidence, presentation, and risk factors for sodium valproate-associated hyperammonemia in neurosurgical patients: a prospective, observational study","volume":"144","author":"Woo","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.yebeh.2021.107967_b0060","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1097\/MJT.0000000000000706","article-title":"Levocarnitine for the treatment of valproic acid-induced hyperammonemic encephalopathy in children: the experience of a large, tertiary care pediatric hospital and a poison center","volume":"26","author":"Glatstein","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.yebeh.2021.107967_b0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0404.1992.tb05085.x","article-title":"Carbamyl phosphate synthetase-l deficiency discovered after valproic acid-induced coma","volume":"86","author":"Verbiest","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107967_b0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1684\/epd.2013.0575","article-title":"Valproic acid-induced hyperammonaemic coma and unrecognised portosystemic shunt","volume":"15","author":"Nzwalo","year":"2013","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2021.107967_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3340\/jkns.2015.58.2.159","article-title":"Valproic acid-induced hyperammonemic encephalopathy as a cause of neurologic deterioration after unruptured aneurysm surgery","volume":"58","author":"Lee","year":"2015","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.yebeh.2021.107967_b0080","first-page":"72","article-title":"Valproic acid induced hyperammonaemic encephalopathy","volume":"63","author":"Amanat","year":"2013","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.yebeh.2021.107967_b0085","first-page":"258","article-title":"Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy","volume":"59","author":"Yamada","year":"2019","journal-title":"Clin Neurol"},{"key":"10.1016\/j.yebeh.2021.107967_b0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0404.2006.00793.x","article-title":"Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy","volume":"116","author":"Velio\u011flu","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107967_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-2-13","article-title":"Valproic acid-induced hyperammonemic encephalopathy - A potentially fatal adverse drug reaction","volume":"2","author":"Sousa","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.yebeh.2021.107967_b0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.jcp.0000264973.77581.61","article-title":"Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy","volume":"27","author":"Nicolai","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2021.107967_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/410403","article-title":"Hyperammonemic encephalopathy due to valproic acid and topiramate interaction","volume":"2014","author":"Twilla","year":"2014","journal-title":"Case Rep Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/NRL.0000000000000166","article-title":"Valproate-induced hyperammonemic encephalopathy presenting as catatonia","volume":"23","author":"P\u00e9rez-Esparza","year":"2018","journal-title":"Neurologist"},{"key":"10.1016\/j.yebeh.2021.107967_b0115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1528-1157.2000.tb00263.x","article-title":"Valproic acid-induced hyperammonemic encephalopathy with triphasic waves","volume":"41","author":"Kifune","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107967_b0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pediatrneurol.2016.12.011","article-title":"Burst suppression pattern on electroencephalogram secondary to valproic acid-induced hyperammonemic encephalopathy","volume":"73","author":"Cherian","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2021.107967_b0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjopharm.2011.09.002","article-title":"Valproic acidInduced parkinsonism in the elderly: a comprehensive review of the literature","volume":"9","author":"Mahmoud","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.yebeh.2021.107967_b0130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2013.03.016","article-title":"Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia","volume":"19","author":"Silver","year":"2013","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.yebeh.2021.107967_b0135","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2021.107967_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/njcp.njcp_120_18","article-title":"Valproic acid-induced nocturnal enuresis in pediatric patients","volume":"22","author":"Ozan","year":"2019","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.yebeh.2021.107967_b0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5214\/ans.0972.7531.210210","article-title":"Non-hyperammonemic valproate encephalopathy","volume":"21","author":"Farooq","year":"2014","journal-title":"Ann Neurosci"},{"key":"10.1016\/j.yebeh.2021.107967_b0150","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/0004867416640906","article-title":"Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting","volume":"50","author":"Dawson","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0155","first-page":"430","article-title":"Lesson of the month 1: Sodium valproate-induced encephalopathy","volume":"18","author":"Camilleri","year":"2018","journal-title":"Clin Med J R Coll Physicians London"},{"key":"10.1016\/j.yebeh.2021.107967_b0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","article-title":"Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy","volume":"69","author":"Mock","year":"2012","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.yebeh.2021.107967_b0165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/cc3742","article-title":"Science review: Carnitine in the treatment of valproic acid-induced toxicity - What is the evidence?","volume":"9","author":"Lheureux","year":"2005","journal-title":"Crit Care"},{"key":"10.1016\/j.yebeh.2021.107967_b0170","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.51.1.292","article-title":"Fulminant progression of demyelinating disease after valproate-induced encephalopathy","volume":"51","author":"Blindauer","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107967_b0175","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0140-6736(80)91773-0","article-title":"Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy","volume":"1","author":"Coulter","year":"1980","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.yebeh.2021.107967_b0180","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1528-1157.2002.42201.x","article-title":"Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy","volume":"43","author":"Ziyeh","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107967_b0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3122\/jabfm.2007.05.070062","article-title":"Valproate-associated hyperammonemic encephalopathy","volume":"20","author":"Wadzinski","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.yebeh.2021.107967_b0190","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1503\/cmaj.061272","article-title":"A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver","volume":"177","author":"Alqahtani","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.yebeh.2021.107967_b0195","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/aas.12136","article-title":"Hyperammonaemic encephalopathy and a flat electroencephalogram caused by valproic acid","volume":"57","author":"Belze","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.yebeh.2021.107967_b0200","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3109\/0886022X.2014.900423","article-title":"Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient","volume":"36","author":"Melexopoulou","year":"2014","journal-title":"Ren Fail"},{"key":"10.1016\/j.yebeh.2021.107967_b0205","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10072-016-2673-z","article-title":"A case with hyperammonemic encephalopathy triggered by single dose valproate","volume":"37","author":"Ciftci","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2021.107967_b0210","doi-asserted-by":"crossref","unstructured":"Farooq F, Din JS, Khan AM, Naqvi S, Shagufta S. Valproate-induced hyperammonemic encephalopathy case presentation 2017;9:8\u201311. https:\/\/doi.org\/10.7759\/cureus.1593.","DOI":"10.7759\/cureus.1593"},{"key":"10.1016\/j.yebeh.2021.107967_b0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2011\/969505","article-title":"A case of valproate induced hyperammonemic encephalopathy","volume":"2011","author":"Tarafdar","year":"2011","journal-title":"Case Rep Med"},{"key":"10.1016\/j.yebeh.2021.107967_b0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2190\/XW8E-Q283-4429-QL71","article-title":"Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report","volume":"33","author":"Elgudin","year":"2003","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.yebeh.2021.107967_b0225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ebcr.2015.08.006","article-title":"Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9","volume":"4","author":"Nagy","year":"2015","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2021.107967_b0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FTD.0000000000000574","article-title":"Catalase C-262T polymorphism is a risk factor for valproic acid-induced abnormal liver function in Chinese patients with epilepsy","volume":"41","author":"Ma","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2021.107967_b0235","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/MJT.0b013e3182053ee1","article-title":"Valproate-induced hyperammonemic encephalopathy: a case report and brief review of the literature","volume":"20","author":"Sunkavalli","year":"2013","journal-title":"Am J Ther"},{"key":"10.1016\/j.yebeh.2021.107967_b0240","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1176\/appi.ajp.2007.07081270","article-title":"Hyperammonemia and valproic acid-induced encephalopathy","volume":"164","author":"Modjtahedi","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0245","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0404.2007.00974.x","article-title":"Encephalopathy induced by levetiracetam added to valproate","volume":"117","author":"Bauer","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107967_b0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14581\/jer.14017","article-title":"Valproic acid-induced hyperammonemic encephalopathy promoted by levetiracetam","volume":"4","author":"Roh","year":"2014","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107967_b0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4212\/cjhp.v68i1.1425","article-title":"Encephalopathy induced by combination therapy with valproic acid and topiramate: challenging the utility of serum ammonia measurement","volume":"68","author":"Sin","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.yebeh.2021.107967_b0260","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1526-4610.2012.02213.x","article-title":"Topiramate-valproate-induced encephalopathy in migraine","volume":"52","author":"Chakor","year":"2012","journal-title":"Headache"},{"key":"10.1016\/j.yebeh.2021.107967_b0265","first-page":"1","article-title":"Hypoxic respiratory failure due to hyperammonemic encephalopathy induced by concurrent use of valproic acid and topiramate, a case report and review of the literature","volume":"25","author":"Raru","year":"2018","journal-title":"Respir Med Case Reports"},{"key":"10.1016\/j.yebeh.2021.107967_b0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/104012371602800106","article-title":"Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients","volume":"28","author":"Thomas","year":"2016","journal-title":"Ann Clin Psychiatry Off J Am Acad Clin Psychiatr"},{"key":"10.1016\/j.yebeh.2021.107967_b0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/20009666.2018.1514933","article-title":"Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review","volume":"8","author":"Gayam","year":"2018","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.yebeh.2021.107967_b0280","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(81)92338-2","article-title":"Sodium valproate and ornithine carbamyl transferase deficiency","volume":"1","author":"Tripp","year":"1981","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.yebeh.2021.107967_b0285","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp.64.5.680","article-title":"Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency","volume":"64","author":"Oechsner","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0290","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S0140-6736(99)01433-6","article-title":"Clumsiness, confusion, coma, and valproate","volume":"353","author":"Ellaway","year":"1999","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.yebeh.2021.107967_b0295","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/ndt\/17.7.1351","article-title":"Deepening coma in an epileptic patient: the missing link to the urea cycle","volume":"17","author":"Vainstein","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.yebeh.2021.107967_b0300","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1176\/appi.neuropsych.12090218","article-title":"Valproate-induced hyperammonemic encephalopathy followed by benzodiazepine withdrawal in a patient with schizoaffective disorder: a differential diagnosis","volume":"25","author":"Sarlon","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.yebeh.2021.107967_b0305","first-page":"2013","article-title":"Encephalopathy in an infant with infantile spasms: possible role of valproate toxicity","author":"Sivathanu","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2021.107967_b0310","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.comppsych.2012.11.001","article-title":"Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012","volume":"54","author":"Cheng","year":"2013","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1600-0404.2003.00227.x","article-title":"Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam","volume":"109","author":"Lokrantz","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107967_b0320","first-page":"389","article-title":"A case of hyperammonaemic encephalopathy due to valproic acid","volume":"69","author":"Prins","year":"2011","journal-title":"Neth J Med"},{"key":"10.1016\/j.yebeh.2021.107967_b0325","doi-asserted-by":"crossref","first-page":"452.e5","DOI":"10.1016\/j.genhosppsych.2012.11.009","article-title":"Risperidone, a risk factor for valproate-induced encephalopathy?","volume":"35","author":"Rodrigues-Silva","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0330","doi-asserted-by":"crossref","first-page":"40","DOI":"10.64719\/pb.4355","article-title":"Reversible encephalopathy due to valproic acid induced hyperammonemia in a patient with bipolar I disorder: a cautionary report","volume":"47","author":"Patel","year":"2017","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.yebeh.2021.107967_b0335","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1176\/jnp.23.1.jnpe22","article-title":"Valproate-induced encephalopathy related to concurrent antimanic medications","volume":"23","author":"Trojak","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.yebeh.2021.107967_b0340","doi-asserted-by":"crossref","first-page":"105894","DOI":"10.1016\/j.clineuro.2020.105894","article-title":"Valproic acid and zonisamide induced hyperammonemic encephalopathy","volume":"196","author":"Ilieva","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2021.107967_b0345","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.yebeh.2011.05.006","article-title":"Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism","volume":"21","author":"Gomez-Iba\u00f1ez","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107967_b0350","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/jnnp.61.2.211","article-title":"Valproate induced encephalopathy treated with carnitine in an adult [10]","volume":"61","author":"Beversdorf","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107967_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2015-210727","article-title":"Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency","volume":"2015","author":"Al-Sharefi","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2021.107967_b0360","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/postgradmedj-2018-136029","article-title":"Severe hyperammonaemic encephalopathy resulting from the overlap between hepatic and valproate encephalopathy","volume":"94","author":"Firouzabadi","year":"2018","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2021.107967_b0365","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4997\/jrcpe.2019.410","article-title":"L-carnitine supplementation as a potential therapy for suspected hyperammonaemic encephalopathy","volume":"49","author":"Khakwani","year":"2019","journal-title":"J R Coll Physicians Edinb"},{"key":"10.1016\/j.yebeh.2021.107967_b0370","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2015.1035441","article-title":"Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"53","author":"Ghannoum","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.yebeh.2021.107967_b0375","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/0972-5229.136076","article-title":"Severe valproate induced hyperammonemic encephalopathy successfully managed with peritoneal dialysis","volume":"18","author":"Kumar","year":"2014","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.yebeh.2021.107967_b0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13256-020-2343-x","article-title":"Valproate-induced hyperammonemic encephalopathy: a case report","volume":"14","author":"Shah","year":"2020","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.yebeh.2021.107967_b0385","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jocn.2013.04.033","article-title":"Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine","volume":"21","author":"Rigamonti","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2021.107967_b0390","article-title":"Hyperammonemic coma after craniotomy: hepatic encephalopathy from upper gastrointestinal hemorrhage or valproate side effect?","volume":"96","author":"Guo","year":"2017","journal-title":"Med (United States)"},{"key":"10.1016\/j.yebeh.2021.107967_b0395","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jocn.2010.08.022","article-title":"Progressive encephalopathy with cerebral oedema and infarctions associated with valproate and diazepam overdose","volume":"18","author":"Rupasinghe","year":"2011","journal-title":"J Clin Neurosci"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:37:54Z","timestamp":1761503874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021002018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":79,"alternative-id":["S1525505021002018"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107967","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107967"}}